Dr. Demir Baykal, MD

Dr. Baykal practices at Piedmont Heart Institute in Lawrenceville, Georgia.

Dr. Baykal's NPI, 1336158104, was assigned on August 7, 2006. Dr. Baykal holds Georgia license 35543.

Dr. Baykal's primary practice is Piedmont Heart Institute, at 766 Walther Rd Suite 100 Suite 100, Lawrenceville, GA 30046-8765. The practice phone is (770) 736-6300.

Dr. Baykal's primary practice is Piedmont Heart Institute in Lawrenceville, Georgia. Dr. Baykal is also affiliated with Northside Hospital Gwinnett. The medical group on file is Piedmont Heart Institute. Dmand AI also links Dr. Baykal to 4 more hospitals, 2 group practices and clinics, 2 medical groups and 1 physician office, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Baykal practices, 9 sites in all. Vendor and product names are available with a free account.

Cardiovascular disease is Dr. Baykal's primary specialty in the NPI Registry, under taxonomy code 207RC0000X. Dr. Baykal is licensed in Georgia.

CMS data shows 2,796 Medicare services from Dr. Baykal across 26 procedure codes in 2024, for 839 Medicare patients. Medicare paid $213,157 for them.

CMS counts 839 Medicare patients who saw Dr. Baykal in 2024. The largest group is 75 to 84, with 319 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 23% are also on Medicaid. Their average risk score is 2.36, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Baykal's median patient age at 65, with 54% women.

In 2024, Dr. Baykal wrote 8,076 Medicare Part D claims for 830 patients. 84% of them were for generic drugs. CMS names the drug for 7,753 of them, across 78 drugs with 11 or more claims each, at $5,050,754 in total drug cost. In 2023, CMS named 7,714 claims across 72 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 92 out of 100 for Dr. Baykal for performance year 2024, reported through an alternative payment model (APM). Dr. Baykal accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links Dr. Baykal to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Pulmonary Arterial Hypertension and Hypertension, Pulmonary.

CMS Open Payments shows 549 general payments to Dr. Baykal from 43 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 69% of the total. United Therapeutics Corporation paid the most, $81,016.